References
- Aisenberg AC. Problems in Hodgkin's disease management. Blood 1999;93:761–779.
- Allan DS, Keeney M, Howson-Jan K, . Number of viable CD34+ cells reinfused predict engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2002;29:967–972.
- Bender JG, To LB, Williams S, . Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992;1:329–341.
- Siena S, Schiavo R, Pedrazzoli P, . Therapeutic relevance of CD34+ cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000;18:1360–1377.
- Shpall EJ, Champlin R, Glaspy JA. Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998;4:84–92.
- Jantunen E, Lemoli M. Preemptive use of plerixafor in difficult- to-mobilize patients: an emerging concept. Transfusion 2012;52:906–914.
- Canales M, Fernandez-Jimenez M, Martin A, . Identification of factors associated with poor peripheral blood progenitor cell mobilization in Hodgkin's disease. Haematologica 2001;86:494–498.
- DiPersio JF, Stadtmayer EA, Nademanee A, .;3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009;113:5720–5726.
- DiPersio JF, Micallef I, Stiff PJ, . Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009;27:4767–4773.
- Cashen A, Lopez S, Gao F, . A phase II study of plerixafor (AMD3100) plus G-CSF for autologus hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant 2008;14:1253–1261.